These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21890777)

  • 1. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy.
    Westergaard RP; Kirk GD; Richesson DR; Galai N; Mehta SH
    Clin Infect Dis; 2011 Oct; 53(7):725-31. PubMed ID: 21890777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.
    Milloy MJ; Kerr T; Buxton J; Rhodes T; Krusi A; Guillemi S; Hogg R; Montaner J; Wood E
    J Acquir Immune Defic Syndr; 2012 Apr; 59(4):393-9. PubMed ID: 22134149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.
    Westergaard RP; Hess T; Astemborski J; Mehta SH; Kirk GD
    AIDS; 2013 Oct; 27(16):2559-66. PubMed ID: 23770493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.
    Meyer JP; Cepeda J; Wu J; Trestman RL; Altice FL; Springer SA
    JAMA Intern Med; 2014 May; 174(5):721-9. PubMed ID: 24687044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis.
    Milloy MJ; Kerr T; Salters K; Samji H; Guillemi S; Montaner J; Wood E
    BMC Infect Dis; 2013 Dec; 13():565. PubMed ID: 24289651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-reported antiretroviral therapy in injection drug users.
    Celentano DD; Vlahov D; Cohn S; Shadle VM; Obasanjo O; Moore RD
    JAMA; 1998 Aug; 280(6):544-6. PubMed ID: 9707145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.
    Milloy MJ; Kerr T; Buxton J; Rhodes T; Guillemi S; Hogg R; Montaner J; Wood E
    J Infect Dis; 2011 May; 203(9):1215-21. PubMed ID: 21459814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent incarceration independently associated with syringe sharing by injection drug users.
    Wood E; Li K; Small W; Montaner JS; Schechter MT; Kerr T
    Public Health Rep; 2005; 120(2):150-6. PubMed ID: 15842116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China.
    Leng X; Liang S; Ma Y; Dong Y; Kan W; Goan D; Hsi JH; Liao L; Wang J; He C; Zhang H; Xing H; Ruan Y; Shao Y
    BMJ Open; 2014 Oct; 4(10):e005886. PubMed ID: 25319999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
    Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
    AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
    Palepu A; Tyndall MW; Li K; Yip B; O'Shaughnessy MV; Schechter MT; Montaner JS; Hogg RS
    J Urban Health; 2003 Dec; 80(4):667-75. PubMed ID: 14709714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.
    Lucas GM; Chaisson RE; Moore RD
    Ann Intern Med; 1999 Jul; 131(2):81-7. PubMed ID: 10419445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incarceration and risk for HIV infection among injection drug users in Bangkok.
    Choopanya K; Des Jarlais DC; Vanichseni S; Kitayaporn D; Mock PA; Raktham S; Hireanras K; Heyward WL; Sujarita S; Mastro TD
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):86-94. PubMed ID: 11782595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
    Anema A; Kerr T; Milloy MJ; Feng C; Montaner JS; Wood E
    AIDS Care; 2014 Apr; 26(4):459-65. PubMed ID: 24015838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
    Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
    HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.
    Krüsi A; Milloy MJ; Kerr T; Zhang R; Guillemi S; Hogg R; Montaner J; Wood E
    Antivir Ther; 2010; 15(5):789-96. PubMed ID: 20710061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
    Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
    BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.